Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next ...

PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA ...

HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong ...

On this first week of clinical rotations as a medical student, my fears surrounding evaluation were nothing short of ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

Key Points - GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates. GAAP loss per share ...

If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ever tested in will be a human.

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...